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B-Cell Depletion Immunotherapy in Pemphigus:
Effects on Cellular and Humoral Immune Responses
Hugo Mouquet1,2,8, Philippe Musette1,2,3,8, Marie-Lyse Gougeon4, Serge Jacquot1,2, Brigitte Lemercier4,
Annick Lim4, Danie`le Gilbert1,2, Ingrid Dutot1,2, Jean C. Roujeau5, Michel D’Incan6, Christophe Bedane7,
Franc¸ois Tron1,2 and Pascal Joly1,2,3
Pemphigus are B-cell-mediated autoimmune diseases affecting skin and mucous membranes. They are
characterized by the production of pathogenic autoantibodies directed against desmogleins (Dsg). In this
prospective study, we treated 21 pemphigus patients with rituximab and analyzed immunological modifications
induced by anti-CD20 immunotherapy. The total depletion of peripheral B cells led to a significant decrease of total
serum IgM but not IgG levels. The B-cell depletion was followed by a progressive re-emergence of naive blood B
lymphocytes, with one-third of them expressing a transitional CD19þCD38highCD24high phenotype. In most
patients, clinical response to rituximab was closely related to the evolution of anti-Dsg autoantibodies that
decreased in patients who achieved complete remission, whereas they remained unchanged or reincreased in
relapsing patients. In contrast, serum antimicrobial IgG remained stable after rituximab treatment. B-cell repertoire
analysis of three patients using immunoscope showed distortions of VH-IgM and VH-IgG immunoscope profiles
before treatment, particularly clonal and oligoclonal expansions in some VH families, which were not found after
B-cell reconstitution, following anti-CD20 immunotherapy. The depletion of autoreactive B cells leading to the
elimination of anti-Dsg autoantibodies in most remitted patients and the restoration of a diverse B-cell repertoire by
naive B lymphocytes may provide an explanation for the long-lasting efficacy of rituximab in pemphigus patients.
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INTRODUCTION
Rituximab (Mabthera, Rituxan) is a chimeric IgG1 mAb that
targets the CD20 molecule, a transmembrane glycoprotein
expressed exclusively in normal and malignant B cells. CD20
expression is regulated during B-cell development in late pre-
B cells and extinguished on plasma cells (Riley and
Sliwkowski, 2000). Rituximab is highly effective for in vivo
B-cell depletion (Reff et al., 1994) and was originally
approved for the treatment of B-cell non-Hodgkin’s lympho-
ma (Cheson, 2002). It has since become a promising
therapeutic approach for other B-cell malignancies. Rituxi-
mab may also be used in B-cell-mediated autoimmune
diseases by depleting pathogenic or antigen-presenting B
cells. Indeed, rituximab has been demonstrated to be
effective in the treatment of rheumatoid arthritis (Leandro
et al., 2002), systemic lupus erythematosus (Looney et al.,
2005), dermatomyositis (Levine, 2005), autoimmune hemo-
lytic anemia (Zecca et al., 2003), immune thrombocytopenic
purpura (Stasi et al., 2001; Giagounidis et al., 2002; Cooper
et al., 2004), acquired hemophilia (Stasi et al., 2004),
Wegener’s granulomatosis (Specks et al., 2001), and mixed
cryoglobulinemia (Sansonno et al., 2003).
Pemphigus are mucocutaneous autoimmune diseases
mediated by IgG autoantibodies directed against keratinocyte
adhesion molecules (Martel and Joly, 2001). Two main
classical subtypes of pemphigus have been individualized,
pemphigus vulgaris (PV) and pemphigus foliaceus (PF), in
which pathogenic autoantibodies are directed against des-
mosomal transmembrane glycoproteins belonging to the
cadherin family, desmoglein 3 (Dsg3), and desmoglein 1
(Dsg1), respectively. Although the autoimmune response in
the mucosal form of PV is directed against Dsg3, in the
mucocutaneous form of the disease, both Dsg1 and Dsg3 are
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targeted by autoantibodies (Mahoney et al., 1999; Amagai
et al., 1999b). The autoantibody responses are directed
against conformational calcium-dependent epitopes of the
Dsg extracellular domain, particularly the N-terminal adhe-
sive region (extracellular 1 and 2 domains) (Sekiguchi et al.,
2001). Anti-Dsg autoantibodies, mainly IgG4 and IgG1, are
pathogenic. Their in vivo binding to their targets after transfer
into normal mice leads to the loss of adhesion between
keratinocytes and the formation of intraepidermal blisters
(Roscoe et al., 1985; Amagai et al., 1992, 1994, 1995).
Over the past few years, the authors and others have
reported the successful treatment of pemphigus patients by
anti-CD20 immunotherapy (Ahmed et al., 2006; Cianchini
et al., 2007; Joly et al., 2007b). We have treated pemphigus
patients with a simple regimen of one cycle of rituximab in a
prospective study, with a 3-year follow-up period. Twenty-
one patients presenting with PV (n¼14) or PF (n¼7) were
included. The outcome of these patients was recently
reported (Joly et al., 2007b). After 3 months, 12 of 14
patients with PV and 6 of 7 with PF experienced complete
remission (CR). Nine patients, including 6 patients with PV
and 3 with PF relapsed after a mean of 18.9±7.9 months.
After a median follow-up of 36 months, 18 patients (86%)
were free of disease, including 10 patients with minimal
corticosteroid (CS) doses: ‘‘CR on minimal therapy’’ of the
Consensus Statement (Murrell et al., 2008; and 8 patients
without steroids treatment: ‘‘CR off therapy’’ of the Consensus
Statement (Joly et al., 2007a, b).
To evaluate the effects of rituximab on cellular and
humoral immune responses, we determined the number and
phenotype of B, T, and NK lymphocytes during the 2-year
follow-up period. To analyze the evolution of antibody
responses, we determined the following: (i) serum levels of
total IgG and IgM; (ii) anti-Dsg1 and anti-Dsg3 autoantibody
titers; (iii) serum levels of anti-tetanus toxoid (TT) and anti-
pneumococcal capsular polysaccharide (PCP) antibodies.
Finally, using the immunoscope method, we assessed the
IgM and IgG B-cell repertoire before treatment and after
B-cell reconstitution following rituximab treatment.
RESULTS
Rituximab induced a dramatic depletion of peripheral B cells
leading to a drop of serum IgM
Twenty-one days after rituximab treatment, a complete
depletion of peripheral B cells was observed in all but two
patients, one of whom relapsed on day 120. B-cell depletion
lasted between 6 and 12 months after treatment. The total
number of CD19þ cells in peripheral blood decreased
significantly, from a median of 298 106 l1 (range
29–752106 l1) at baseline to 0 106 l1 (range
0–1 106 l1) on day 21 (Figure 1a). The frequency of
peripheral blood B cells was similar regardless of anti-
CD19, anti-CD20, or anti-CD22 mAbs used. The frequency
of peripheral blood B cells decreased significantly, from a
median of 11.2% (range 3.3–28.7%) at baseline to 0% (range
0–0.5%) on day 21 (data not shown). Both the total number
and the frequency of CD19þ lymphocytes in peripheral
blood remained unchanged between day 21 and month 4.
Interestingly, only 10% of patients had recovered their initial
total number/frequency of blood B cells 1 year after rituximab
infusion. Moreover, 2 years after treatment, median B-cell
count remained twofold lower than at baseline (106106 l1
vs 298 106 l1) (Figure 1a).
Next, we determined by immunonephelemetry the IgM
and IgG levels in patient sera before and after rituximab
treatment. Whereas mean serum level of IgG was not
modified after rituximab treatment, IgM levels progressively
decreased from baseline to day 540 (1.58±1 vs
0.75±0.47 g l1) (Figure 1b).
Reappearance of peripheral naive and transitional B cells
during B-cell reconstitution after rituximab therapy
The phenotype of peripheral blood B cells was compared
before and after rituximab treatment (Figure S1). B-cell
reconstitution started between month 6 and month 9
(Figure 1) and was mainly composed of B cells with a naive
CD19þCD27 phenotype (Figure 2a). In fact, the frequency
of CD19þCD27 cells increased from a median of 65.2%
(range 35.1–95.3%) before treatment to 91.6% (range
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Figure 1. B-cell and immunoglobulin. (a) Evolution of B-cell numbers and
(b) total immunoglobulin levels in pemphigus patients treated by rituximab.
(a) The horizontal line within each box is the median total number of
peripheral blood B cells in pemphigus patients (n¼21). The boxes represent
the 25th and 75th percentiles and the whiskers represent the 5th and 95th
percentiles of the measured values. The total depletion of peripheral B cells
was observed in all but two patients from day 21 to month 6. The B-cell
reconstitution in peripheral blood of treated patients started between month
6 and month 9. (b) Total IgG (&) and IgM (’) levels were measured in patient
sera by immunonephelemetry. Error bar represents standard error of the
mean (SEM) (n¼ 20 for days 0, 180, and 360; n¼ 9 for days 540 and 720).
Concentration of IgM but not IgG was significantly reduced in patient sera
after rituximab therapy as compared with baseline. **Po0.01, ***Po0.001.
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80.8–99.1%) after B-cell recovery. Interestingly, the
frequency of peripheral B cells expressing CD38high and
CD5, both markers of the transitional B-cell stage, increased
from a median of 11.9% (range 3.2–24.8%) and 0% (range
0–15.5%) before treatment to 52.5% (range 35.6–78.8%) and
40.6% (range 25.8–98%), respectively, after B-cell recovery
(Figure 2b and c). More precisely, approximately 30% of re-
emerging B cells had a CD19þCD38highCD24high transi-
tional phenotype (Figure 2d), which is characteristic of
human B-cell emigrants from bone marrow that develop in
periphery. It is noteworthy that reappearing B cells slightly
overexpressed the CD23 low-affinity IgE receptor (P¼0.018)
(data not shown). No significant changes in the frequency of
activated B cells (CD19þCD86þ ) were observed between
the pre- and post-treatment periods (data not shown).
The frequency of peripheral CD19þCD27, CD19þ
CD5þ , and CD19þCD38high B-cell subpopulations was
then analyzed over a long time duration from the B-cell
reconstitution up to 24 months after treatment. Figure 2
shows that the frequency of CD19þCD5þ B cells decreased
from 52.5 to 20.2% (P¼ 0.002), whereas CD19þCD27
B cells did not significantly change (P¼0.09). Further-
more, the frequencies of CD19þCD38high and CD19þ
CD38highCD24high B cells also decreased from 40.5 and
29.4% to 12.2 and 12.5%, respectively (P¼ 0.0002 and
P¼0.0004) (Figure 2c and d).
Evolution of the B-cell repertoire after rituximab therapy
The complete VH-IgM and VH-IgG B-cell repertoires were
analyzed using the immunoscope method (Lim et al., 2008),
in 3 and 2 rituximab-responder patients, respectively
(Table 1). Among the eight VH families analyzed, only the
major ones (VH3a, VH3b, and VH4) are presented (Table 1,
Figure 3). Before treatment, no difference in the frequency
of VH family usage for IgM was detected in PF patient P05.
In contrast, PF patient P20 showed an increased frequency of
VH4 family usage and proportionally decreased frequencies
of VH3a/b usages, as compared with healthy controls. An
increased frequency of VH4 usage in the IgG B-cell repertoire
was also observed in this patient before treatment. Interest-
ingly, VH3b and VH4 family usages for both IgM and IgG
were completely normalized after rituximab treatment, in this
patient (Table 1). Conversely, although the IgM- and IgG-VH
family usages in B cells from PV patient P21 were similar to
those found in controls, VH3b usage for IgM was decreased
and VH3a/b usages for IgG were increased in this patient,
after rituximab treatment (Table 1).
Figure 3 shows the diversity of the BCR repertoire through
the visualization of the complementarity determining region
3 (CDR3) length distribution for each VH-Cm or VH-Cg
rearrangement. For the IgM B-cell repertoire, a polyclonal
distribution of the CDR3 with, however, some expanded
CDR3 peaks was observed in 2 out of 3 patients before
rituximab treatment (that is, VH3b in P5 and P20, VH3a in
P20). Interestingly, the increased VH4 usage in P20 was
associated with a major clonal expansion (Figure 3a and
Table 1). Although the IgM-expressing B cells from P21 had a
normal CDR3 length distribution before treatment, IgG
immunoscope profiles showed expansion peaks in all VH
families (Figure 3b). Furthermore, the same major expansions
detected in VH3b- and VH4- IgMþ B cells of P20 were
observed in the IgGþ B cells. Sequence analysis of these
CDR3 bands demonstrated the presence of highly recurrent
sequences, suggesting the existence of three major B-cell
clones in the blood from P20 before rituximab (Table 2).
Following rituximab therapy, all the expansions detected in
the IgM and IgG B-cell repertoires were no longer detected,
and the immunoscope profiles were typically Gaussian for all
VH families. These data indicated that the reconstitution of B
lymphocytes following anti-CD20 immunotherapy was asso-
ciated with the restoration of the BCR repertoire diversity in
remitted patients, with a distribution of the CDR3 length that
was identical to the one found in blood B cells from healthy
controls (Figure 3) and in blood cord B cells (data not shown).
Rituximab induced a decrease of anti-Dsg autoantibodies,
but did not affect the production of antimicrobial antibodies
Autoantibody responses in pemphigus patients treated by
rituximab were evaluated using recombinant Dsg1 and Dsg3
ELISA assays. First, a dramatic decrease of anti-Dsg1 and anti-
Dsg3 IgG antibodies was observed after rituximab treatment
in 5 of 6 PF (83%) and in 8 of 12 PV (75%) patients who
achieved CR, respectively (Figure 4a). Persistent high Dsg1
ELISA values were detected in the one PF patient with
treatment failure, and in another PF patient who achieved CR
after rituximab treatment but relapsed early in the evolution
at day 180. Persistent high titers of anti-Dsg3 antibodies were
detected in the two PV patients in partial remission and in
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Figure 2. Phenotypes of reappearing B cells in pemphigus patients following
rituximab therapy. The panels show the frequencies of peripheral blood B
cells expressing (a) CD27, (b) CD5, (c) CD38, and (d) CD38highCD24high,
determined by flow cytometry analysis in pemphigus patients at three
different time points: (i) baseline; (ii) B-cell repopulation phase; and (iii) a long
time after B-cell repopulation (18 to 24 months post-treatment). During the
B-cell reconstitution phase (months 6–9 after rituximab), a majority (B92%)
of peripheral B cells expressed a naive phenotype (CD19þCD27), and
half of them expressed the CD5 molecule. During this period, transitional
B cells (CD38highCD24high population) represented more than 30% of
re-emerging B cells.
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two PV patients who achieved clinical remission. During the
evolution, high titers of anti-Dsg3 and anti-Dsg1 antibodies
were detected in three and four patients with mucosal and
cutaneous relapse, respectively (Figure 4b). Surprisingly,
5 out of 12 (41.7%) PV patients had persistent high titers
or a reincrease of anti-Dsg3 antibodies, while still being in
CR (Figure 4a).
To disentangle this discrepancy, we first analyzed the
evolution of anti-Dsg3 IgG subclasses from PV patients with
persistent high titers of anti-Dsg3 antibodies. Before treat-
ment, anti-Dsg3 IgG4 antibodies were predominantly found
(Figure 4c). Anti-Dsg3 IgG4 antibodies were also detected in
serum from PV patients, with mucosal relapses. Surprisingly,
anti Dsg3 IgG4 antibodies were also evidenced in the serum
from PV patients with ongoing clinical remission, up to 1 year
after rituximab treatment, when B cells had remerged
(Figure 4c). The sera that failed to decline Dsg3 ELISA values
despite ongoing clinical remission of mucosal lesions were
retested using higher dilutions. After determination of the
optimal dilution, a decrease of 56 and 57% of Dsg3 ELISA
values was observed during the first year after rituximab
treatment in two out of the five highly diluted sera tested,
whereas ELISA values of the three other sera remained stable
overtime. Interestingly, Dsg3 ELISA values of the two sera that
initially declined, progressively reincreased during the
second year of follow-up, up to 78 and 153% of baseline
values (Figure S2).
In contrast to the marked changes of anti-Dsg antibody
titers in patients treated by rituximab, serum levels of
antimicrobial antibodies, that is, anti-PCP and anti-TT
antibodies, were not significantly modified after treatment
(Figure 4d).
Table 1. Clinical characteristics, autoantibody profile, and relative quantification of VH B-cell families of
pemphigus patients
P051 P20 P212
Day 0 Day 240* Day 0 Day 500* Day 0 Day 600*
Type of pemphigus PF PF PV
Response to rituximab3 CR CR CR
Clinical phenotype
Cutaneous lesions4 20% None 20% None 10% None
Mucous lesions None None None None + None
Prednisone dose (mg day1) 0 0 20 5 20 3
Autoantibody titers5
Anti-Dsg1 225 216 136 16 89 36
Anti-Dsg3 — — — — — —
VH family usage6 Control7
IgM
VH3a 5 8 0.7 3.8 3 6 6.8±2.5
VH3b 81 67 16 53 76 43 72.5±9.2
VH4 14 25 48 18 16 29 18.1±6.7
IgG
VH3a ND ND 0.1 0.03 0.2 0.5 0.17±0.14
VH3b ND ND 2.1 1 3 8.2 1.63±0.55
VH4 ND ND 1 0.2 0.2 0.6 0.41±0.43
1Patient P05 had a localized skin relapse at day 180. This relapse was treated with topical corticosteroids and skin lesions rapidly healed within 10 days. He
was again in clinical remission at day 240 when the B-cell repertoire analysis was performed.
2Patient P21 initially had a phenotype of PV. She was treated by rituximab after a relapse corresponding clinically and histologically to a herpetiform
pemphigus, which is a subtype of PF, explaining the absence of anti-Dsg3 antibodies.
3Evaluations were validated at the time point (*) when the B-cell repertoire analyses were performed (CR: complete remission).
4Values correspond to the means of body surface area involved.
5Values were determined by ELISA assays and are expressed in units per milliter of sera (Uml1) (—, nonsignificant values).
6The mean frequency of VH utilization (compared to all 7 VH families) was determined by quantitative real-time PCR analysis for B cells from patients before
(day 0) and after rituximab (*).
7Control values correspond to the mean percentages of VH utilizations obtained from four different healthy donors.
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No impact of B-cell depletion on the number and
phenotype of T-cell subpopulations and NK cells
The absolute numbers of peripheral blood CD3þ T cells,
CD4þ T cells, and NK cells did not vary significantly from
baseline to day 21 and remained unchanged during 1 year
after the B-cell depletion therapy (Figure S3a). In addition, no
significant differences were detected in the different blood
T-cell subpopulations after treatment (Figure S3b). Next, we
analyzed whether rituximab therapy could modify the pattern
of cytokines produced by T cells. The frequencies of CD4þ
and CD8þ T-cells producing interferon-g, IL-2, and tumor
necrosis factor-a did not change significantly from baseline to
months 2, 6, and 12 after rituximab treatment (Figure S3c).
DISCUSSION
In this study, we extended the clinical observation of pem-
phigus patients treated with rituximab (Joly et al., 2007a, b),
by analyzing immunological modifications induced by anti-
CD20 immunotherapy in PV and PF patients. Rituximab
induced a profound depletion of peripheral blood B cells that
lasted at least 6 months in most patients. Interestingly, the
median number of B cells remained below the baseline count
up to 1–2 years after treatment. Significantly, this B-cell
kinetic was very similar to that described previously in
patients with B-cell lymphoma (Piro et al., 1999; Anolik
et al., 2007) or other B-cell-mediated autoimmune diseases
treated with rituximab (Roll et al., 2006). The B-cell depletion
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Figure 3. Effect of rituximab on the B-cell repertoire of pemphigus patients. (a) IgM and (b) IgG B-cell repertoires were studied in pemphigus patients
before and after rituximab using the immunoscope method as detailed in Materials and Methods. Peripheral blood mononuclear cells from three pemphigus
patients (P05, P20, and P21) were obtained before rituximab treatment and during CR period (day 240, 500, and 600, respectively). Patient characteristics are
described in Table 1. IgG immunoscope analysis was undertaken only for two patients, 1 PV and 1 PF (P20 and P21, respectively). Peripheral blood
mononuclear cells from four healthy donors used as control for normal B-cell repertoire were also subjected to immunoscope profiling for IgM and IgG.
Representative VH B-cell profiles are shown for one healthy control. The x axis of immunoscope profiles (spectratypes) indicates CDR3 length, wheeras the
y axis displays arbitrary fluorescence intensity of the run-off products. Distortions of the immunoscope profile or contracted spectratypes consisting of 1–4 peaks
suggesting the presence of B-cell expansions in patients with active disease are indicated by the arrows. Several immunoscope anomalies (expanded peaks or
oligoclonal patterns) turn off to polyclonal profiles in remitted patients after the B-cell depletion therapy.
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induced by rituximab in pemphigus patients led to a
significant decrease of the total IgM but not IgG serum
levels, as reported previously in patients with lymphoma
(McLaughlin et al., 1998), rheumatoid arthritis (Cambridge
et al., 2003), or systemic lupus erythematosus (Vallerskog
et al., 2007) treated with rituximab. This rapid decrease is in
accordance with the short half-life of IgM. It might be
explained, by the disappearance of IgM-expressing mature B
cells, which are known to express CD20. As both short- and
long-lived plasma cells do not express CD20 (Radbruch et al.,
2006), Vallerskog et al. (2007) proposed that IgM could be
produced by plasmablasts or short-lived plama cells, whereas
most IgG-secreting plasma cells are long-lived, explaining the
absence of medication of whole IgG level after rituximab
treatment.
The reappearance of naive B cells (92%) with an increased
expression of CD5 and CD38high, which are both expressed
in transitional B cells, has been described previously during
the B-cell repopulation phase in rheumatoid arthritis patients
treated by rituximab (Leandro et al., 2006). It suggests that the
re-emergence of peripheral B cells is due to the production of
immature B cells in the bone marrow. Indeed, as shown
previously in patients with other autoimmune diseases or
lymphoma treated by rituximab (Leandro et al., 2006; Roll
et al., 2006; Anolik et al., 2007; Sutter et al., 2008), a high
frequency of reappearing B cells from pemphigus patients
overexpressed both the CD38 and CD24 molecules, a
phenotype that has recently been shown to identify transi-
tional B cells (CD19þCD38highCD24high) (Carsetti et al.,
2004; Sims et al., 2005; Cuss et al., 2006; Marie-Cardine
et al., 2008). Interestingly, it has been demonstrated that
peripheral mature B cells are derived from these transitional B
cells (Marie-Cardine et al., 2008). Thus, we postulate that the
B-cell phenotype observed during the B-cell reconstitution
corresponds to bone marrow-derived repopulation, which
reappeared in patient blood after the B-cell depletion
induced by rituximab.
To detect potential abnormalities in IgM- and IgG-
expressing B cells from patients with active disease, which
could be reverted after rituximab therapy, we used an original
immunoscope method to study the B-cell repertoire. Before
treatment, VH B-cell repertoire analysis showed both
oligoclonal and clonal expansions of immunoscope profiles,
that is, for P05 and P20 in IgM (2/3 patients) and, for P20 and
P21 in IgG (2/2 patients). Strikingly, the major expansions
observed in VH-IgM profiles were also detected in VH
families of IgGþ B cells of P20. Thus, the three major clones
detected in the expanded B-cell populations may reflect
antigen-driven clonal B-cell expansions. Interestingly, recent
studies showed that anti-Dsg1/3 autoantibodies are geneti-
cally characterized by restricted patterns of Ig gene usage and
antigen-induced somatic hypermutations (Payne et al., 2005;
Qian et al., 2007). Nevertheless, analysis of the CDR3
sequences of predominant blood B-cell clones from PF
patient P20 did not show any identity/homology with those
described for anti-Dsg1 antibodies (Payne et al., 2005).
Following rituximab therapy, these expansions were no
longer detected and immunoscope profiles were typically
Gaussian for all VH families, indicating that the B-cell
reconstitution was associated with the restoration of a diverse
BCR repertoire in remitted patients. Thus, our results
indicated that rituximab treatment abrogates clonal and
Table 2. Analysis of the B-cell clonal expansions in a patient with active PF (P20)
1 The purified CDR3 bands (11 aa or 12 aa) corresponding to expanded peaks were subjected to exhaustive sequencing as previously described (Lim et al, 2008).  
2 Frequencies of redundant aminoacid sequences and clone sequences were estimated among those contained in the same CRD3 peak or Ig isotype.    
IgM VH3b ARDWDDNGVLFDY 51% ARDWDD(N/T)GVLFDY 58% - 2.2% 
(16%) 
   %7 YDFLVGTDDWDRA
IgG VH3b ARDWDDNGVLFDY 50% ARDWDD(N/T)GVLFDY 80% - 0.5% 
(2.1%) 
   %03 YDFLVGTDDWDRA
IgM VH4  ATCMVQGDIVWFDP 33.4% A(T/S)CMVQGDIVWFDP 41% - 17% 
 (48%) ASCIAVAGTFFFDY 8% ASCI(A/G)VAGTFFFDY 15% - 6% 
   %6.7 PDFWVIVGQVMCSA
   %8.6 YDFFFTGAVGICSA
   %8.3 YDFYYSGSLGIVSA
IgG VH4  ATCMVQGDIVWFDP 30% A(T/S)CMVQGDIVWFDP 26% - 0.1% 
  )%1(
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oligoclonal expansions observed in pemphigus patients
during active phase of the disease and thus, led to the
emergence of a new repertoire in remitted patients. This may
account for the long-lasting remissions observed in some
patients after only one cycle of rituximab (Joly et al.,
2007a, b).
Although serum levels of total IgG were unchanged,
we examined the effect of rituximab treatment on anti-Dsg
IgG autoantibody response. Clinical response to rituximab
was closely related to the evolution of anti-Dsg1 antibodies
that dramatically decreased in all patients who achieved CR,
whereas they remained unchanged or reincreased after
treatment in relapsing patients. On the other hand, persistent
high titers of anti-Dsg3 antibodies were observed in 5 of 12
PV patients (41.7%) who maintained a CR as described
previously (Arin et al., 2005). Additional experiments using
highly diluted sera confirmed that these sera contained high
titers of anti-Dsg3 antibodies, as a transient decrease of Dsg3
antibodies followed by a reincrease of Dsg3 ELISA values was
observed in two out of these five sera, whereas Dsg3 ELISA
values of the three other sera remained stable overtime.
Although discrepancies between the ELISA score and the
disease severity have been occasionally reported (Harman
et al., 2001; Ishii et al., 2005), in most cases, a close
correlation between ELISA anti-Dsg1/3 antibody titers and
disease activity has been reported in PV patients (Ishii et al.,
1997; Amagai et al., 1999a; Cheng et al., 2002). Thus, as
pathogenic anti-Dsg1/3 autoantibodies usually belong to the
IgG4 subclass, we then analyzed the serum IgG-subclasses
from the PV patients in CR with persistent high levels of
anti-Dsg3 IgG antibodies. Surprisingly, no modification of
anti-Dsg3 IgG-subclasses was evidenced after rituximab
treatment, as anti-Dsg3 IgG4 antibodies were detected both
in patients with active disease and in those in CR. Therefore,
a switch from IgG4 to a non-pathogenic IgG subclass did not
account for the discrepancy observed between clinical
response and the persistence of anti-Dsg3 antibodies in some
patients. On the other hand, compelling evidences tend to
demonstrate that epitopes bound by anti-Dsg autoantibodies
determine their pathogenic activities and disease activity in
pemphigus patients (Sekiguchi et al., 2001; Li et al., 2003;
Tsunoda et al., 2003). We demonstrated in our initial report
that sera from PV patients in CR after rituximab, with
persistent high levels of anti-Dsg3 antibodies, no longer
recognized the pathogenic epitopes that were targeted during
active phase of the disease (Joly et al., 2007a, b). Such a
phenomenon has been described previously in endemic PF
(Li et al., 2003).
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Figure 4. Evolution of anti-Dsg and anti-microbial IgG antibody titers in sera of pemphigus patients treated with rituximab. Anti-Dsg antibody titers in 20
pemphigus patients before and after treatment by rituximab were determined by ELISA using recombinant Dsg1 and Dsg3. ELISAs were performed according
to the manufacturer’s procedures with 1:100-diluted pemphigus sera. Anti-Dsg1 and anti-Dsg3 antibody titers in PF and PV patients with (a) persistent
complete remission (CR) or (b) cutaneous/mucosal relapses during the evolution (arrows). The graph in the upper right part of panel a depicts persistent high titers
or a re-increase of anti-Dsg3 antibodies in five PV patients with ongoing CR. (c) IgG subclasses of anti-Dsg3 antibodies in patients with persistent anti-Dsg3
antibody titers and those in CR (n¼ 4) or with mucosal relapses (n¼ 3) were determined before rituximab treatment (0) and after 1 year (360). Vertical bar
represents the mean of optical density (OD) obtained for each IgG subclass by ELISA assay and error bar represents SEM. (d) Anti-tetanus toxoid (TT) antibodies
and anti-pneumococcal capsular polysaccharide (PCP) antibodies were measured by ELISA in 10 patient sera. Vertical bar represents the mean of anti-TT or
anti-PCP antibody levels and error bar represents SEM. All comparisons made with Wilcoxon’s test for anti-TT and anti-PCP antibodies are nonsignificant.
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In contrast to the dramatic decrease of anti-Dsg antibody
titers observed in most patients having obtained CR, serum
levels of anti-TT and anti-PCP antibodies remained stable
following rituximab therapy, which may account for the low
number of severe infections reported in these patients. Similar
observations have been reported previously in rheumatoid
arthritis patients treated with rituximab. Indeed, titers of IgM
rheumatoid factor and anti-citrullinated peptide autoantibo-
dies was significantly reduced with rituximab, whereas those
of anti-PCP and anti-TT antibodies remained unchanged
(Cambridge et al., 2003, 2006; De Vita et al., 2002).
Similarly, B-cell depletion in systemic lupus erythematosus
patients led to a decrease of anti-nucleosome and anti-
dsDNA antibodies, whereas anti-TT and anti-PCP antibody
levels did not change significantly after rituximab treatment
(Cambridge et al., 2006). The persistence of protective
antibodies induced by vaccine or infection after rituximab
therapy suggests that these antibody populations may be
secreted by long-lived plasma cells. Autoantibodies, in turn,
can be secreted by both long-lived and short-lived plasma
cells. The development of these later cells can be stopped by
anti-CD20 immunotherapy, which induces a B-cell depletion
(Odendahl et al., 2000). Indeed, the existence of long-lived
autoreactive plasma cells has been demonstrated in the
murine NZB/W model of human systemic lupus erythema-
tosus (Hoyer et al., 2004). In these mice, both short- and long-
lived autoreactive plasma cells, constantly generated de novo
and contributed to the maintenance of autoantibody level,
that is, anti-dsDNA antibodies. The presence of long-life
autoantibody-secreting plasma cells might explain the
persistence of anti-Dsg antibodies in some patient sera. In
transgenic mice expressing human CD20, which was used to
mimic B-cell depletion observed in humans, the presence of
some factors, that is, B-cell-activating factor belonging to the
tumor necrosis factor family (BAFF)/Blys, contributes to the
resistance of splenic marginal zone and germinal center B
cells to rituximab (Gong et al., 2005). Thus, the different
susceptibility of autoreactive B cells to rituximab may also be
explained by their microanatomic location.
Numerous studies have reported modifications of the
frequencies of several T-cell subsets in patients with
autoimmune diseases after rituximab therapy (Cross et al.,
2006; Stasi et al., 2007; Vallerskog et al., 2007). Although
autoreactive B cells require cooperation with Dsg-reactive
T cells to produce anti-Dsg autoantibodies in pemphigus
(Hertl et al., 2006), we demonstrated that the frequencies of
T-cell subpopulations in patient blood were not affected by
the B-cell depletion. However, one should note that we did
not focus on changes in the number and phenotype of
regulatory or Dsg3-specific autoreactive T cells. Eming et al.
(2006) have observed a significant reduction of Dsg3-specific
T cells secreting interferon-g in some pemphigus patients
following rituximab therapy.
Overall, this study demonstrates that therapeutic effect of
rituximab therapy in patients with pemphigus involves the
following: (i) the elimination of autoreactive B cells, which
in turn leads to a reduction of anti-Dsg antibodies in a
majority of patients; (ii) the reappearance of naive B cells
characterized by a normal repertoire, which may explain the
long-term recovery observed in a part of patients.
MATERIALS AND METHODS
Patients and treatment
Patients with severe PV or PF who fulfilled the classical clinical,
histological, and immunological diagnostic criteria (Lever, 1979)
were eligible for inclusion if the following criteria were met:
(i) lack of response to an 8-week treatment with prednisone
1.5mg kg1 day1 (recalcitrant cases); (ii) occurrence of at least
two relapses during the decrease of CS doses despite a minimal
prednisone dose of 20mgday1 (CS-dependent cases); or (iii) con-
traindication to CS due to severe associated medical conditions
(contraindication to CS). Thirteen French dermatology departments
participated in this prospective open trial. This study was approved
by the Ethics Committee of Seine Maritime and conducted according
to the Declaration of Helsinki Principles. Written informed consent
was obtained from each patient. This trial is registered at
www.clincaltrials.gov (NCT00213512) (Joly et al., 2007b).
Patients were treated with one cycle of four weekly infusions of
rituximab at a dosage of 375mgm2 of body surface area on days 1,
8, 15, and 22. CS doses were maintained at the initial dose until
patients were clinically free of disease; CS doses were then gradually
reduced by 10% twice a month, except for patients with contra-
indication to CS who were treated with rituximab alone. CR of
disease was defined according to the Consensus Statement on
Definition of Disease Endpoints and Therapeutic Response for
Pemphigus (Murrell et al., 2008) as ‘‘the absence of new or
established lesions’’, and the healing of all skin and mucosal lesions
with complete epithelialization ‘‘CR off therapy’’ means that patients
were off all systemic therapy. ‘‘CR on therapy’’ means that patients
were still receiving minimal therapy. Relapse was defined as the
occurrence of new cutaneous blisters or oral erosions during
treatment. Other therapy that might affect the activity of pemphigus
such as intravenous infusions of immune globulin, dapsone, or
immunosuppressive drugs was avoided throughout the study period.
Follow-up measurements
Patients were evaluated both clinically and biologically every month
during the first year of follow-up and every other month during the
second year. The primary end point was the rate of ‘‘complete
remission therapy’’ 3 months after the last infusion of rituximab.
Flow cytometry analysis
The following fluorochrome-labeled mAbs were obtained from
commercial sources: anti-CD3, anti-CD4, anti-CD19, anti-CD20,
anti-CD21, anti-CD22, anti-CD23, anti-CD5, anti-CD27, anti-
CD38, anti-CD24, anti-CD56, anti-CD86, anti-CD25, anti-CD26,
antiCD28, anti-CD38, anti-CD45RA, anti-CD45RO, anti-CD71,
anti-DR (Beckman Coulter, Miami, FL); anti-CD27, anti-CD70,
anti-CD134 (BD Biosciences Pharmingen, San Diego, CA); anti-
CD69 (Becton Dickinson, Franklin Lakes, NJ). Heparinized peri-
pheral blood samples were obtained from pemphigus patients and
stained for B, T lymphocytes, and NK cells using matched
combinations of fluorescein isothiocyanate (FITC)-, phycoerythrin-,
or phycoerythrin-Cy5- conjugated anti-human mAbs. Cell labeling
was performed by mixing 100 ml of whole blood with each specific
combination of mAbs and maintained for 20minutes at room
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temperature in the dark. Red cells were lysed using TQ-prep system
(Beckman Coulter). The samples were washed in phosphate-buffered
saline for 5minutes, centrifuged at 2,000 r.p.m. for 5minutes, and
resuspended in 500ml of phosphate-buffered saline. Flow cytometry
analysis was performed on Epics Elite flow cytometer (Beckman
Coulter). Lymphocytes were gated according to forward-scatter/side-
scatter parameters and fluorescence intensity data were collected on
104-gated lymphocytes. Appropriate conjugated isotype-matched
mAbs were used as controls (Beckman Coulter) and stained less than
5% of the cell population.
Intracellular detection of cytokines was performed in peripheral
blood mononuclear cells activated with 25 ngml1 of phorbol 12-
myristate 13-acetate, 1 mgml1 of ionomycin and 10 mgml1 of
Brefeldin-A (Sigma, Saint Louis, MO). Cells were then fixed and
permeabilized using the IntraPrep reagents (Immunotech, Marseille,
France) according to the manufacturer’s instructions. Cells were
incubated with phycoerythrin-coupled anti-IL-2, anti-tumor necrosis
factor-a (BD Biosciences Pharmingen), or anti-interferon-g (Beckman
Coulter) mAbs and analyzed by Epics Elite flow cytometer (Beckman
Coulter).
Serum concentrations of IgM and IgG
Serum concentrations of IgM and IgG were determined by
immunonephelemetry using BN Prospec II system (Dade Berhing,
Deerfield, IL) according to the manufacturer’s instructions.
Dsg-specific ELISA assay
To determine anti-Dsg1 and anti-Dsg3 antibody titers, Dsg1- and
Dsg3-ELISA tests (MESACUP Desmoglein test, Medical and Bio-
logical Laboratories, Nagano, Japan) were performed with 1:100-
diluted pemphigus sera according to the manufacturer’s instructions.
Data are expressed as units per milliter of sera (Uml1). Anti-Dsg1
and anti-Dsg3 values superior to 20 and 14Uml1, respectively,
were considered as positive. Optimal serum dilutions for PV patients
who achieved CR with high anti-Dsg3 Ab titers were determined
before treatment using serially diluted sera from 1:100 to 1:2,000.
The optimized index values were calculated by multiplying the
obtained index values by the dilution factor (Cheng et al., 2002).
For IgG-subclass determination, the plates were alternatively
incubated with 5,000-fold-diluted mouse monoclonal anti-human
IgG1, IgG2, IgG3, or IgG4 antibody (Sigma) for 1 hour at room
temperature. After washing, the plates were incubated with
peroxydase-conjugated goat anti-mouse IgG (1:100,000) (Rockland,
Gilbertsville, PA) for 30minutes and color development was
achieved following the manufacturer’s instructions.
Serum levels of antimicrobial antibodies
Serum levels of IgG anti-TT and anti-PCP antibodies were
determined by ELISA as described previously (Ballet et al., 1987).
Analysis of BCR repertoire
Total RNA was prepared from peripheral blood mononuclear cells
using the RNeasy kit (Sigma, Deisenhofen, Germany). RNA was
converted into cDNA following standard protocols by using Super-
script II (Invitrogen, Carlsbad, CA, USA), oligo dT primers
(Eurogentech, Paris, France), and RNAsin (Invitrogen). PCR reactions
were carried out by combining a primer and a specific fluorophore-
labeled probe for the constant region CHm with one of eight primers
covering the different VH1-7 genes. Reactions were carried out using
the Taqman 7300 (Applied Biosystems, Foster City, CA) and standard
reagents from Applied Biosystems. Details of the primers and the
calculation of the relative transcriptions are filed as European and US
patent (Repertoire determination of a lymphocyte B population, WO
2005/059176 A1) and can be obtained through the Pasteur Institute,
Paris, France (Lim et al., 2008). PCR products were then subjected to
run-off reactions with a nested fluorescent primer specific for the
constant region gene. The fluorescent products were separated and
analyzed on an ABI-PRISM 3730 DNA analyzer. The size and
intensity of each band were analyzed with Immunoscope software
(Pannetier et al., 1993). Fluorescence intensity of each band was
plotted in arbitrary units on the y axis, whereas the x axis
corresponds to the CDR3 length in amino acids. Amplification
products (bands with CDR3 lengths of 11 and 12 aminoacids in the
VH3b and VH4 family, respectively) corresponding to the clonal
expansions observed in P20 immunoscope profiles were cloned,
sequenced, and analyzed according to the procedure described
previously (Lim et al., 2008).
Statistical analysis
All analyses were performed with Wilcoxon’s matched pairs signed
rank test and Kruskal–Wallis test except for the comparison of
CD38highCD24high B-cell frequencies, which were analyzed with the
Mann–Whitney test. P-values o0.05 were considered statistically
significant.
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Figure S1. Flow cytometry analysis of B-cell phenotype in pemphigus patients
treated by rituximab.
Figure S2. Evolution of anti-Dsg3 autoantibodies in PV patients ongoing CR.
Figure S3. (a) Total numbers of peripheral blood T-cells, CD4þ T-cells, and
NK cells, (b) frequencies of CD4þ T-cell subpopulations, and (c) frequencies
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